MARKET

CTSO

CTSO

Cytosorbents Corp
NASDAQ
0.9500
+0.0201
+2.16%
After Hours: 0.9900 +0.04 +4.21% 16:12 03/28 EDT
OPEN
0.9100
PREV CLOSE
0.9299
HIGH
0.9600
LOW
0.8624
VOLUME
116.41K
TURNOVER
0
52 WEEK HIGH
4.290
52 WEEK LOW
0.8400
MARKET CAP
51.58M
P/E (TTM)
-1.4881
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CTSO last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CTSO last week (0311-0315)?
Weekly Report · 03/18 11:13
Cytosorbents Price Target Maintained With a $1.00/Share by HC Wainwright & Co.
Dow Jones · 03/15 10:50
HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
Benzinga · 03/15 10:40
Cytosorbents Financial and Clinical Study Outlook: Maintaining a Hold Rating
TipRanks · 03/15 10:27
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CytoSorbents reported earnings per share of -12 cents. The company reported revenue of $8.70 million. This was 6.25% worse than the analyst estimate for the company to report revenue of -10 million. The stock was down 2.7% after the market closed.
Investorplace · 03/15 01:53
Cytosorbents Corp reports results for the quarter ended in December - Earnings Summary
Cytosorbents Corp reports results for the quarter ended in December. Revenue fell 7.7% to $8.67 million from a year ago. The company reported a quarterly adjusted loss of 13 cents per share. The mean expectation of four analysts was for a loss of 14 cents.
Reuters · 03/14 23:20
Press Release: CytoSorbents Reports Fourth -4-
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids. The Company's technologies have received non-dilutive funding of approximately $50 million from DARPA.
Dow Jones · 03/14 20:39
More
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.

Webull offers Cytosorbents Corp stock information, including NASDAQ: CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.